DOCSLIB.ORG

Concurrent Ki-67 and P53 Immunolabeling in Cutaneous

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Concurrent Ki-67 and P53 Immunolabeling in Cutaneous Concurrent Ki-67 and p53 Immunolabeling in Cutaneous Melanocytic Neoplasms: An Adjunct for Recognition of the Vertical Growth Phase in Malignant Melanomas? Zahid Kaleem, M.D., Anne C. Lind, M.D., Peter A. Humphrey, M.D., Ph.D., Robert H. Sueper, M.D., Paul E. Swanson, M.D., Jon H. Ritter, M.D., Mark R. Wick, M.D. Lauren V. Ackerman Laboratory of Surgical Pathology, Washington University Medical Center (ZK, ACL, PAH, PES, JHR), and SmithKline-Beecham Laboratories (RHS), St. Louis, Missouri; and the Robert E. Fechner Laboratory of Surgical Pathology, University of Virginia Health Sciences Center (MRW), Charlottesville, Virginia malignant melanocytic tumor representing the ver- Ki-67 labeling of paraffin sections has been corre- tical growth phase—nodular melanoma—demon- lated with the number of cells in non-Go phases of strated a statistically significant difference from all the replicative cell cycle, and this immunohisto- other lesions in this study with respect to Ki-67 ,␹2) and p53 reactivity (P < .000001 ,008. ؍ chemical technique has been applied to the evalu- index (P ation of a variety of human neoplasms. Similarly, ␹2). Subsequent concurrent use of a Ki-67 threshold immunolabeling for p53 protein has been used to index of 10% and a p53 index of 5% correctly indi- detect mutations in the corresponding gene, as a cated the presence of vertical growth in 75% of reflection of possible cellular transformation in the NMMs, whereas only 8% of radial growth phase same context. Both of these techniques were ap- melanomas of other types were colabeled at the plied to 253 melanocytic tumors of the skin to assess same levels of reactivity for the two markers (P < their possible utility in the diagnosis and subcatego- .00001, ␹2). Thus, although the distinction between rization of such lesions. They included 76 banal benign and malignant melanocytic tumors could (common) nevi (CN), 39 Spitz nevi (SN), 62 superfi- and should not be based on immunohistology for cial spreading malignant melanomas in radial Ki-67 and p53, these results suggest that the latter growth (SSMMs), 32 nodular malignant melanomas determinants may, in fact, be used as an adjunct to (NMMs), 21 lentigo maligna melanomas in radial morphology in the recognition of the vertical growth (LMMs), and 23 melanomas arising in asso- growth phase in cutaneous malignant melanomas. ciation with preexisting compound nevi (MCN). One hundred cells were counted randomly in each tu- KEY WORDS: Ki-67, Melanocytic neoplasms, Mela- mor, and dark, exclusively nuclear reactivity was noma, Nevi, p53, Skin neoplasms. scored as positive labeling; results were recorded as Mod Pathol 2000;13(3):217–222 percentages. Negligible Ki-67 and p53 labeling was seen in CN and SN, at a level that was similar to that In attempts to extend morphologic observations in obtained in cases of LMM and MCN. The largest the prediction of biologic behavior, several adjunc- proportion of Ki-67–positive and p53-positive cells tive techniques have been applied to cutaneous was observed in NMMs, followed by SSMMs. Radial melanocytic lesions of all types. These procedures growth-phase SSMMs and LMMs demonstrated im- munoprofiles that were similar to those of melano- have included nuclear morphometry (1); immuno- cytic nevi, and MCN did so as well. The prototypical staining for p53 proteins (2–4), the INK4A/CDKN2 tumor suppressor gene product (5), proliferating cell nuclear antigen (6–8), or the Ki-67 nuclear protein (9–13); and histochemical analysis of nu- Copyright © 2000 by The United States and Canadian Academy of Pathology, Inc. cleolar organizer regions (14). VOL. 13, NO. 3, P. 217, 2000 Printed in the U.S.A. A particularly challenging facet of dermatopa- Date of acceptance: July 29, 1999. Presented in part at the scientific session of the 34th annual meeting of thology concerns the more narrow setting of mela- the American Society of Dermatopathology, San Francisco, CA, March nocytic malignancy. In that context, it is important 1997. Address reprint requests to: Mark R. Wick, M.D., Division of Surgical to identify the growth phases (radial or vertical) of Pathology, Room 3882 Old Medical School, University of Virginia Health Sciences Center, Jefferson Park Avenue, Box 214, Charlottesville, VA melanomas, in recognition of the prognostic im- 22908; e-mail: [email protected]; fax: 804-924-0217. portance attached to them (15). Our laboratory has 217 previously studied the expression of putatively mu- The various tumors were categorically distributed tant p53 protein in melanocytic lesions and found a as follows: 76 common nevi (CN), 39 Spitz nevi reasonable correlation between its presence and (SN), 62 superficial spreading malignant melano- malignant morphologic and biologic characteris- mas (SSMMs), 32 nodular malignant melanoma tics; moreover, non–wild-type p53 protein was also (NMMs), 21 lentigo maligna melanomas (LMMs), preferentially associated with vertical growth and 23 melanomas arising in association with pre- among melanomas of various types (2). Relatively existing common nevi (MCN). Each of the nodular few reports have addressed the identification of melanomas was, by definition, in the vertical growth phases in cutaneous melanocytic tumors growth phase, whereas all other melanomas in the using the MIB1 (anti–Ki-67) antibody (9), and none study were, by design, radial growth phase lesions. has discussed its concomitant application with p53 Paraffin sections of all specimens were cut at 4 ␮ in this context. Moreover, the issue of whether pro- thickness and mounted on glass slides coated with liferation indices and p53 are truly helpful in the poly-L-lysine (Sigma-Aldrich Chemical Co., St. diagnostic distinction between melanocytic nevi Louis, MO). They were dewaxed in xylene and ab- and melanomas is still unsettled, in part because of solute ethanol; incubated for 30 min in methanolic methodological differences in various publications H2O2 (0.3% [v/v]) to quench endogenous peroxi- (6–13). Hence, the specific aim of the following dase; and rehydrated by passage through graded evaluation was 2-fold: first, to reassess the utility of ethanol solutions, distilled water, and phosphate- concurrent labeling evaluation for Ki-67 and p53 in buffered-saline (PBS; pH 7.4). Heat-mediated “an- the differential diagnosis of benign and malignant tigen retrieval” (17) was undertaken after immer- melanocytic neoplasms, and, second, to study the sion of the slides in standard citrate buffer (0.01 M; differences, if any, in the labeling indices for these pH 6.0). They were warmed for 12 min in a micro- markers in various biologic subgroups of cutaneous wave oven (Sharp, Los Angeles, CA; 600 W; 2,450 melanoma. The latter included “common” lesions MHz). After a 20-min cooling period, the sections in the radial and vertical growth phases (as defined were rinsed in water and incubated in PBS. The by Elder & Murphy [16]), as well as other examples MIB-1 antibody to Ki-67 (Dako Co., Carpinteria, CA; of recognized histologic melanoma variants. A cur- dilution 1:300) and a “cocktail” of anti-p53 reagents rently advocated microwave-mediated enhance- (clone designations 1801 and D07; BioGenex Co., ment method (17) was used to optimize exposure of Dublin, CA, and Dako, respectively) were then ap- the Ki-67 and p53 target epitopes in standard par- plied and the sections were incubated for 16 hours affin sections. at 4° C. Antibody bridge assembly with the avidin- biotin-peroxidase complex (ABC) technique, using the Elite ABC kit (Vector Laboratories; Burlingame, MATERIALS AND METHODS CA), was carried out on the next day by sequential 1-h incubations. Chromogenic development was A total of 253 well-characterized cutaneous mela- obtained by immersion of the sections in nickel nocytic neoplasms were studied, as obtained from chloride–complexed 3,3Ј-diaminobenzidine solu- the surgical pathology files of Washington Univer- tion (0.25 mg/mL with 0.003% H2O2) for a maxi- sity Medical Center and SmithKline-Beecham Lab- mum of 10 min. The slides were then lightly coun- oratories (St. Louis, Missouri). These specimens terstained with Harris’s hematoxylin. were procured as excisional biopsies from 101 Positive controls for Ki-67 studies were repre- males and 153 females, ranging in age from 3 to 98 sented by paraffin sections of “stock” neoplasms years, whose lesions had arisen in various locations. that had been previously studied by flow cytometry The samples were obtained with standard surgical to determine proportions of tumor cells in the dif- technique and immediately fixed in neutral- ferent phases of the cell cycle. Similar sections of buffered formalin. Each of these tumors had been neoplasms that had been shown to manifest p53 diagnostically classified originally by at least two of mutations by Southern blot analysis also were used the authors using established morphologic criteria as positive controls. Nonimmune murine ascitic (16). Vertical growth in melanomas was defined by fluid was substituted for the primary antibodies as a the presence of at least one of the following criteria negative control. Cells were considered Ki-67 posi- (16): all tumor cell nests in the epidermis being tive or p53 positive when they demonstrated strong smaller than at least one in the dermis, differing and exclusively nuclear labeling. Those cases with cytologic appearances of the intraepidermal and no reactivity whatsoever were regarded as negative, intradermal components, the presence of dermal whereas immunoreactivity in the others was scored tumor cell nests of 25 or more cells in width, and semiquantitatively (as “1 to 4% ϩ,” “5 to 9% ϩ,” and mitotic activity in intradermal neoplastic cells. Ն10% ϩ, etc.) by assessment of 100 tumor cells in Complete follow-up information was obtained in randomly selected microscopic fields at 400ϫ mag- all instances to validate the nosologic process. nification. Paired categorical results were com- 218 Modern Pathology pared by ␹2 analysis, using True Epistat statistical labeling and a 5% level for concurrent p53 immu- computer software (Epistat Services, Richardson, noreactivity, 24 (75%) of the NMMs in this series TX).
Load more

Recommended publications
  • Critical Evaluation of the So-Called “Junction Nevus”
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector CRITICAL EVALUATION OF THE SO-CALLED "JUNCTION NEVUS* S. WILLIAM BECKER, MS., M.D. The serious study of pigmented nevi was undertaken by many workers in the closing years of the 19th Century. All recognized that the microscopic picture of nevi differed from anything seen in other organs. The presence of nevus cells in both the epidermis and dermis led to concepts of origin at one or the other site, or at both sites. Dermal Origin: Demieville (1) believed that the nevus cells arose from adven- titial and endothelial cells of blood vessels. Bauer (2) and vonRecklinghausen (3) thought that the origin was from endothelium of lymph vessels rather than of blood vessels. Epidermal Origin: According to Abesser (4), Duranti, in 1871, was the first to suggest an epidermal origin of nevus cells. Kromayer (5) stated that the endo- thelium-like cells originate in the basal portion of the epidermis as "Bläschen- zellen", migrate to the dermis and develop connective tissue and elastic fibers, a change which he called "desmoplasia". Abesser (4) agreed that the cells origi- ated in the epithelium and lost their intercellular bridges, but migrated into the dermis as epithelium-like cells, and remained such. Unna (6) advanced the concept that the epithelial cells changed by losing their intercellular bridges and multiplied in groups, a process which he called "Ab- sonderung", then migrated as groups to the dermis, which he called "Abtrop- fung", thus forming pigmented nevi.
    [Show full text]
  • On the Histological Diagnosis and Prognosis of Malignant Melanoma
    J Clin Pathol: first published as 10.1136/jcp.33.2.101 on 1 February 1980. Downloaded from J Clin Pathol 1980, 33: 101-124 On the histological diagnosis and prognosis of malignant melanoma ARNOLD LEVENE Hunterian Professor, Royal College of Surgeons, and Department of Histopathology, The Royal Marsden Hospital, Fulham Road, London SW3, UK SUMMARY This review deals with difficulties of diagnosis in cutaneous malignant melanoma encountered by histopathologists of variable seniority and is based on referred material at The Royal Marsden Hospital over a 20-year period and on the experience of more than two-and-a-half thousand cases referred to The World Health Organisation Melanoma Unit which I reviewed when chairman of the Pathologists' Committee. Though there is reference to the differential diagnosis of primary and metastatic tumour, the main concern is with establishing the diagnosis of primary melanoma to the exclusion of all other lesions. An appendix on recommended diagnostic methods in cutaneous melanomas is included. Among the difficult diagnostic fields in histopathol- not to be labelled malignant because it 'looks nasty'. ogy melanocytic tumours have achieved a notoriety. Thus, until the critical evaluation of the 'malignant Accurate diagnosis, however, is of major clinical melanoma of childhood' by Spitz (1948) the naevus importance for the following reasons: with which this investigator's name is associated was 1 The management of the primary lesion is reckoned among the malignancies on histological principally by surgical excision with a large margin grounds. of normal appearing skin. The consequences of over-diagnosis are those of major disfiguring surgery Naevus and melanoma cells http://jcp.bmj.com/ and its morbidity.
    [Show full text]
  • Lumps & Bumps: Approach to Common Dermatologic Neoplasms
    Case-Based Approach to Common Dermatologic Neoplasms Patrick Retterbush, MD, FAAD Mohs Surgery & Dermatologic Oncology Associate Member of the American College of Mohs Surgery Private Practice: Lockman Dermatology January 27th 2018 Disclosure of Relevant Financial Relationships • I do not have any relevant financial relationships, commercial interests, and/or conflicts of interest regarding the content of this presentation. Goals/Objectives • Recognize common benign growths • Recognize common malignant growths • Useful clues & examination for evaluating melanocytic nevi and when to be concerned for melanoma/atypical moles • How to perform a basic skin biopsy and which method/type to choose • Basic treatment/when to refer Key Questions & Physical Examination Findings for a Growth History Physical Examination • How long has the lesion been • Describing a growth present? – flat or raised? • flat – macule (<1cm) or patch (>1cm) – years, months, weeks • raised – papule (<1cm) or plaque (>1cm) – nodule if deep (majority of lesion in • Has it changed? dermis/SQ) – Size – secondary descriptive features • scaly (hyperkeratosis, retention of strateum – Shape corneum) – Color • crusty (dried serum, blood, or pus on surface) • eroded or ulcerated (partial vs. full thickness – Symptoms – pain, bleeding, itch? epidermal loss) – Over what time frame? • color (skin colored, red, pigmented, pearly) • feel (hard or soft, mobile or fixed) • PMH: • size: i.e. 6 x 4mm – prior skin cancers • Look at the rest of the skin/region of skin • SCC/BCCs vs. melanoma
    [Show full text]
  • How to Optimize Biopsy Pathology of Melanocytic Lesions
    London, Dermatopathology Study Day 04.12.15 Pigmented lesions of sun-damaged skin W.J. Mooi Department of Pathology, VU university medical center, Amsterdam [email protected] Lentigo maligna Lentigo maligna • Defining combination of features: a substantial proliferation of atypical melanocytes predominantly in lentiginous arrangement, limited to the epithelial compartment of sun-damaged skin, and manifesting as a flat, impalpable hyperpigmentation, usually with irregular contours and with variations of pigmentation. • Spread into hair follicles usually present • Ascent of atypical melanocytes commonly present • Nests are absent or present • The epidermis is commonly flat and thin, but rete ridges may be present • Cellularity, ascent, nesting, degree of atypia vary within the same lesion • Lichenoid inflammatory response sometimes Lentigo maligna: some diagnostic problems • Distinction between paucicellular LM and reactive melanocytic hyperplasia in sun-damaged skin • ‘Grading’ of severity; assessment of risk of invasion: compromised by variations within the same lesion • Interpretation of small numbers of dermal melanocytes in conjunction with LM • Small dermal melanocytic naevi • Scattered isolated dermal ? pre-existent melanocytes • Lichenoid inflammatory response obscuring LM Paucicellular lentigo maligna versus reactive melanocyte hyperplasia in sun-damaged skin LENTIGO MALIGNA REACTIVE MELANOCYTIC HYPERPLASIA Lentiginous spread with or without nests Lentiginous spread only; no nests Melanocytes often directly side-to-side Melanocytes
    [Show full text]
  • Dealing with Lentigo Maligna
    Clinical Dealing with lentigo maligna A challenging case Daniel Mazzoni, Jim Muir more likely with larger lesions and those in higher densities with grouping, on the head and neck.1,2 follicular extension, cytological atypia and even pagetoid spread into the CASE ANSWER 2 upper epidermis. This can make the A man aged 46 years presented to a Ill-defined margins and subclinical determination of clearance of lentigo multidisciplinary team (plastic surgery, extension are common with lentigo maligna difficult.5 radiation oncology, dermatology) with a maligna and, as in this case, lead to A crucial principle is to avoid wound year-long history of a lentigo maligna on involved excision margins.3,4 closures that distort the margin until no the right ear lobe. After initial biopsy, the It can be difficult to differentiate further excisions are needed.3,6 Complex lesion had undergone two wide excisions the histopathological appearance of flaps will distort margins and make with his general practitioner (GP). Both atypical melanocytic hyperplasia seen re-excision problematic. Reconstruction excisions showed margin involvement. in sun-damaged skin from lentigo can be delayed until histopathology The GP referred the patient to a radiation maligna.5 Sun-damaged skin can confirms adequate clearance. oncologist. show features in common with lentigo Confocal microscopy can be used to The initial referral resulted in onward maligna. This includes melanocytes attempt to delineate the extent of lentigo referral to the multidisciplinary team for assessment. Examination revealed a well-healed full thickness skin graft with no clinical or dermoscopic evidence of lentigo maligna (Figure 1).
    [Show full text]
  • Lentigo Maligna Melanoma and Simulants Maui January 2020 Superficial Atypical Melanocytic Proliferations
    Superficial Atypical Melanocytic Proliferations II. Lentigo Maligna Melanoma and Simulants Maui January 2020 Superficial Atypical Melanocytic Proliferations • RGP Melanomas • SSM, LMM, ALM, MLM • Intermediate lesions • Dysplastic nevi, Atypical lentiginous proliferations in high CSD skin; Atypical Acral lentiginous nevi • Superficial atypical melanocytic proliferations • Pagetoid plaque-like Spitz nevi; pigmented spindle cell nevus (Reed) • Special site nevi (genital, breast, scalp, ear, flexural, etc). • Superficial atypical melanocytic proliferations of uncertain significance • Atypical/unusual/uncertain examples of all of the above Superficial Atypical Melanocytic Proliferations • RGP Melanomas • SSM, LMM, ALM, MLM • Intermediate lesions • Dysplastic nevi, Atypical lentiginous proliferations in high CSD skin; Atypical Acral lentiginous nevi • Superficial atypical melanocytic proliferations • Pagetoid plaque-like Spitz nevi; pigmented spindle cell nevus (Reed) • Special site nevi (genital, breast, scalp, ear, flexural, etc). • Superficial atypical melanocytic proliferations of uncertain significance • Atypical/unusual/uncertain examples of all of the above High CSD Melanomas and Simulants. D Elder, Maui, HI Jan 2020 Lentigo maligna melanoma Atypical lentiginous nevi/proliferations High CSD: Lentiginous Nevi and Lentigo Maligna Melanoma and Simulant(s) • Lentiginous Melanoma of Sun-Damaged Skin • LMM in situ • LMM invasive • Distinction from Dysplastic Nevi (Dysplastic Nevus-like Melanoma/Nevoid Lentigo Maligna • Lentiginous Nevi of
    [Show full text]
  • Second Revised Proposed Regulation of the State
    SECOND REVISED PROPOSED REGULATION OF THE STATE BOARD OF HEALTH LCB File No. R057-16 February 5, 2018 EXPLANATION – Matter in italics is new; matter in brackets [omitted material] is material to be omitted. AUTHORITY: §§1, 2, 4-9 and 11-15, NRS 457.065 and 457.240; §3, NRS 457.065 and 457.250; §10, NRS 457.065; §16, NRS 439.150, 457.065, 457.250 and 457.260. A REGULATION relating to cancer; revising provisions relating to certain publications adopted by reference by the State Board of Health; revising provisions governing the system for reporting information on cancer and other neoplasms established and maintained by the Chief Medical Officer; establishing the amount and the procedure for the imposition of certain administrative penalties by the Division of Public and Behavioral Health of the Department of Health and Human Services; and providing other matters properly relating thereto. Legislative Counsel’s Digest: Existing law defines the term “cancer” to mean “all malignant neoplasms, regardless of the tissue of origin, including malignant lymphoma and leukemia” and, before the 78th Legislative Session, required the reporting of incidences of cancer. (NRS 457.020, 457.230) Pursuant to Assembly Bill No. 42 of the 78th Legislative Session, the State Board of Health is: (1) authorized to require the reporting of incidences of neoplasms other than cancer, in addition to incidences of cancer, to the system for reporting such information established and maintained by the Chief Medical Officer; and (2) required to establish an administrative penalty to impose against any person who violates certain provisions which govern the abstracting of records of a health care facility relating to the neoplasms the Board requires to be reported.
    [Show full text]
  • Identifying Skin Cancer
    Identifying Skin Cancer Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018 American Cancer Society web site Skin Cancer • Melanoma • Non-Melanoma Skin Cancer – Basal Cell carcinoma – Squamous Cell carcinoma • Merkel cell carcinoma • Angiosarcoma • Lymphoma • Sarcomas, etc Skin Cancer •More people are diagnosed with skin cancer each year in the U.S. than all other cancers combined. •One in five Americans will develop skin cancer by the age of 70.3 •The annual cost of treating skin cancers in the U.S. is estimated at $8.1 billion: about $4.8 billion for nonmelanoma skin cancers and $3.3 billion for melanoma. Information from skin cancer foundation Skin Cancer Mortality rates • The vast majority of skin cancer deaths are from melanoma. • In 2018 in the US, it is estimated that 9,320 deaths will be attributed to melanoma — 5,990 men and 3,330 women. American Cancer Society Non melanoma Skin Cancer Mortality • An estimated 4.3 million cases of BCC are diagnosed in the U.S. each year, resulting in more than 3,000 deaths. • > 1 million cases of SCC are diagnosed in the U.S. each year, resulting in more than 15,000 deaths. Skin Cancer Foundation Melanocytic Tumors Lentigo • Brown macules • No seasonal variation • Melanocyte numbers are increased • Melanocytes singly distributed along the basal layer of the epidermis. Nevi • Go through natural evolution from lentigo to junctional, to compound, to dermal nevus and then may involute. “Dysplastic” Nevi • Synonyms: Atypical nevus, Clark’s
    [Show full text]
  • Treatment and Outcomes of Melanoma in Acral Location in Korean Patients
    DOI 10.3349/ymj.2010.51.4.562 Original Article pISSN: 0513-5796, eISSN: 1976-2437 Yonsei Med J 51(4):562-568, 2010 Treatment and Outcomes of Melanoma in Acral Location in Korean Patients Mi Ryung Roh, Jihyun Kim, and Kee Yang Chung Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea. Received: May 26, 2009 Purpose: A retrospective study was conducted to review the treatment and out- Revised: October 19, 2009 comes of mainly melanomas in acral location in a single institution in Korea, and Accepted: November 4, 2009 to evaluate the prognostic significance of anatomic locations of the tumor. Materials Corresponding author: Dr. Kee Yang Chung, and Methods: A retrospective review was completed on 40 patients between Department of Dermatology and Cutaneous 2001 and 2006 to obtain pertinent demographic data, tumor data, treatment charac- Biology Research Institute, Yonsei University teristics, and follow-up data. Results: Forty melanoma patients were identified College of Medicine, 250 Seongsan-ro, and analyzed. Of these, 18 were male and 22 were female patients and the mean Seodaemun-gu, Seoul 120-752, Korea. age at the time of diagnosis was 55.9 years. Of the tumors, 65% were located on Tel: 82-2-2228-2080, Fax: 82-2-393-9157 the hands and feet with acral lentiginous melanoma being the most common E-mail: [email protected] histological subtype. Univariate analysis for the overall melanoma survival revealed ∙The authors have no financial conflicts of that the thickness of the tumor and the clinical stage have prognostic significances.
    [Show full text]
  • Skin Tumors Process, Starting at Young Age (20 Years), with the Based on Its Differentiation Into Keratinocytic, Tumors Developing 30 to 40 Years Later (Fig 22-2)
    Pathology of Cancer El Bolkainy et al 5th edition, 2016 The skin consists of epidermis, dermis and the Cutaneous malignancies account for nearly half subcutaneous fat. The epidermis contains different of all cancers in the Unites States. In Australia and types of cells each representing a specific lineage. New Zealand, where the incidence of skin cancer These include keratinocytes, melanocytes, is the highest in the world, the total number of Langerhans and Merkel cells (Elder et al, 2005). skin cancer exceeds that of all other cancers The epidermis is divided into 4 layers; stratum combined by several folds (Ch'ng et al, 2006). Non basale (basal cell layer), stratum spinosum (spinous melanoma skin cancer is not registered in USA cell layer), stratum granulosum (granular cell layer), and UK national registries because it is almost and stratum corneum (Fig 22-1). The dermis has 2 curable by simple surgical excision. The variations layers; a superficial (papillary dermis) and deep of incidence in distinct geographic areas are (reticular dermis) layers. The dermis contains probably related to the degree of skin supporting stroma, blood vessels and hemato- pigmentation of the population. The median age at lymphoid cells. The basal layer of the epidermis is diagnosis of skin cancer (excluding basal and attached to the superficial dermis by the basement squamous cell carcinoma) was 61 years (Howlader membrane. There are five appendages in normal et al, 2011). In Egypt, skin cancer constituted 4% skin; hair, nail, apocrine, eccrine, and sebaceous of total malignancies, affects mainly adults with glands. The hair follicle, sebaceous glands and male predominance (1.5:1) (Mokhtar et al, 2007).
    [Show full text]
  • Managing Melanoma in Situ Kristen L
    Managing Melanoma In Situ Kristen L. Toren, MD, and Eric C. Parlette, MD† Melanoma is a highly aggressive skin cancer with an increasing incidence. Melanoma in situ is an early, non-invasive form in which the tumor is confined to the epidermis. Treatment of melanoma in situ is challenging due to the frequent subclinical microscopic spread and to the presentation on the head and neck in cosmetically sensitive areas with chronic sun damage. Optimizing tumor eradication is imperative to reduce the potential progression into invasive disease and metastasis, all while maintaining cosmesis. Multiple treatment regimens have been implemented for managing difficult melanoma in situ tu- mors. We provide a thorough review of surgical, and non-surgical, management of mela- noma in situ which can pose therapeutic dilemmas due to size, anatomic location, and subclinical spread. Semin Cutan Med Surg 29:258-263 © 2010 Elsevier Inc. All rights reserved. elanoma is a highly aggressive form of skin cancer with ciated with a greater risk of melanoma, with the exception of Man increasing incidence.1 Melanoma in situ (MIS) is an lentigo maligna. Lentigo maligna, unlike other melanomas, early form of melanoma in which the malignancy is confined has a greater association with nonmelanoma skin cancers.3 to the epidermis. According to the American Cancer Society, an estimated 68,720 new cases of malignant melanoma were Diagnostic Criteria reported in 2009, and 53,120 new cases of melanoma in situ. Lentigo maligna is a subtype of MIS found on sun-exposed Melanoma in situ can have a highly variable presentation, areas and accounts for approximately 80% of all MIS tu- from a well-demarcated, small brown macule on healthy- mors.2 With its increasing incidence and being a precursor to appearing skin to an asymmetric, variably pigmented large invasive melanoma, the treatment of MIS, in particular len- patch on grossly actinically damaged skin (Fig.
    [Show full text]
  • Guidelines for the Management of Cutaneous Melanoma 2010 J.R
    BJD BAD GUIDELINES British Journal of Dermatology Revised U.K. guidelines for the management of cutaneous melanoma 2010 J.R. Marsden, J.A. Newton-Bishop,* L. Burrows, M. Cook,à P.G. Corrie,§ N.H. Cox,– M.E. Gore,** P. Lorigan, R. MacKie,àà P. Nathan,§§ H. Peach,–– B. Powell*** and C. Walker University Hospital Birmingham, Birmingham B29 6JD, U.K. *University of Leeds, Leeds LS9 7TF, U.K. Salisbury District Hospital, Salisbury SP2 8BJ, U.K. àRoyal Surrey County Hospital NHS Trust, Guildford GU2 7XX, U.K. §Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 2QQ, U.K. –Cumberland Infirmary, Carlisle CA2 7HY, U.K. **Royal Marsden Hospital, London SW3 6JJ, U.K. The Christie NHS Foundation Trust, Manchester M20 4BX, U.K. ààUniversity of Glasgow, Glasgow G12 8QQ, U.K. §§Mount Vernon Hospital, London HA6 2RN, U.K. ––St James’s University Hospital, Leeds LS9 7TF, U.K. ***St George’s Hospital, London SW17 0QT, U.K. Correspondence Disclaimer Jerry Marsden. These guidelines reflect the best published data available at the time the report was E-mail: [email protected] prepared. Caution should be exercised in interpreting the data; the results of future Accepted for publication studies may require alteration of the conclusions or recommendations in this report. 24 May 2010 It may be necessary or even desirable to depart from the guidelines in the interests of Key words specific patients and special circumstances. Just as adherence to the guidelines may not evidence, guideline, investigation, melanoma, treatment constitute defence against a claim of negligence, so deviation from them should not necessarily be deemed negligent.
    [Show full text]